SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp. (ESHA) is trending amidst heightened market attention for low-float SPACs, with traders noting its exceptionally tight share structure and high insider ownership. Community discussion points to significant institutional accumulation and views ESHA as having substantial potential for rapid upward movement, drawing comparisons to other recent high-flying low-float plays.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending sharply lower after receiving a Complete Response Letter from the FDA for its relacorilant drug, intended for Cushing's syndrome. The community is actively debating the severe market reaction, with many expressing disappointment and predicting further downside, while others view the significant dip as a potential buying opportunity. This decision casts a shadow on the company's near-term growth strategy and future pipeline utilizing similar mechanisms, prompting discussions around its market valuation relative to existing revenue and competitors.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending due to the FDA approval of NEREUS, which marks the first new pharmacologic treatment for motion sickness in over four decades and is seen by many as significantly under-modeled by the market. The community is actively discussing its potential for off-label use in addressing GLP-1 induced nausea, positioning it as a major upside driver with billions in market potential and fueling significant speculation about a potential buyout from a larger GL-1 focused pharmaceutical company. This approval, coupled with other pipeline catalysts, signals a significant re-rating opportunity for VNDA as it transitions into a commercial-stage company.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corporation (BULL) is actively trending as investors discuss significant year-end tax loss harvesting contributing to recent price declines. Community sentiment is sharply divided, with optimists highlighting the fintech brokerage's profitability, growing user base, and international expansion as a long-term opportunity, while skeptics warn of persistent dilution and fierce competition.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is gaining significant attention following a regulatory setback for a competitor's Cushing's syndrome drug, Corcept Therapeutics (CORT), which received a Complete Response Letter from the FDA. This news alleviates immediate competitive pressure on Xeris's Recorlev, positioning it for an extended period of market leadership. The community is actively debating the long-term implications for Recorlev's market share and XERS's perceived undervaluation in light of this favorable development.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology ($AFJK) is trending due to extreme volatility, attributed to its low float and a recent short squeeze that broke a month-long downtrend. The community is actively debating its "pump and dump" nature and "casino play" characteristics, comparing it to other highly volatile low-float names like $ESHA and $SMX, as it continues to see significant price movements and trading halts.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is gaining significant attention following the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 for Alzheimer's agitation. This expedited regulatory pathway is sparking considerable investor excitement, with the community highly optimistic about the company's expanding central nervous system pipeline and the continued strong commercial performance of its existing therapies.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is currently trending due to renewed speculation around a potential Mastercard/Zero Hash merger and a significant increase in institutional buying, which some believe signals strong conviction in its payment collateral technology. However, community sentiment is sharply divided, with many expressing frustration over persistent price dips and perceived market manipulation, while others maintain strong belief in its real-world utility and the anticipated impact of the Clarity Act.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Blockchain Inc

Riot Platforms is trending due to a new stock offering, sparking community debate about potential dilution and its impact on share value. Many investors are vocalizing concerns, with some labeling it a "share selling scam" and noting the stock's struggle to align with broader cryptocurrency market trends. Amidst this, there's ongoing discussion about the company's potential to secure AI/datacenter contracts to leverage its energy capacity.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending as reports indicate Nvidia is seeking to significantly ramp up H200 AI chip production with TSMC to meet robust demand from Chinese technology companies. This news highlights TSMC's critical role as the foundational supplier for leading AI chipmakers, driving positive sentiment among investors discussing its expanding capacity and strong institutional support.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SIMO This ticker is entering a stage where execution quality will overshadow headline narratives. Execution gaps should narrow meaningfully over coming quarters. Failure to deliver would likely trigger renewed valuation compression. Execution precision will determine whether this evolves or stalls.

StockTwits Web

Silicon Motion Technology Corp.

 This ticker is entering a stage where execution quality will overshadow headline narratives. Execution gaps should narrow meaningfully over coming quarters. Failure to deliver would likely trigger renewed valuation compression. Execution precision will determine whether this evolves or stalls.